Top ▲
This section gives an overview of the disease, and where available shows the following:
More information can be found in the help pages.
✖Disease ID: | 442 | |
Name: | Huntington disease | |
Associated with: | 2 targets |
Click on the target name to link to its detailed view page
Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.
If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page
Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.
More information can be found in the help pages.
✖C5a1 receptor | |
Comments: | In a rat model of 3-nitropropionic acid-induced Huntington's disease, C5aR inhibition via oral administration of either PMX53 or PMX205 reduced the behavioural phenotype and striatal lesions histologically. A decrease in striatal astrocytosis was also demonstrated, however whether this was a cause or effect of the reduction in striatal lesions was not investigated. |
References: | 2 |
Kir4.1 | |
References: | 1 |
Click ligand name to view ligand summary page
Click the arrow in the final column to expand comments
More information can be found in the help pages.
✖No ligand related data available for Huntington disease
1. Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Haustein MD, Anderson MA, Mody I, Olsen ML, Sofroniew MV et al.. (2014) Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat Neurosci, 17 (5): 694-703. [PMID:24686787]
2. Woodruff TM, Crane JW, Proctor LM, Buller KM, Shek AB, de Vos K, Pollitt S, Williams HM, Shiels IA, Monk PN et al.. (2006) Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J, 20 (9): 1407-17. [PMID:16816116]